News | Heart Failure | December 29, 2015

BioVentrix Announces 30th Clinical Case for Revivent-TC Heart Failure Intervention

Less invasive procedure reduces size of left ventricle

BioVentrix, Revivent-TC Ventricular Enhancement System, interventional heart failure

BioVentrix closed-chest Revivent-TC Ventricular Enhancement System reduces the size of the ventricle for more efficient pumping in heart failure patients.

December 29, 2015 — BioVentrix in mid-December announced the successful completion of the 30th clinical case using the closed-chest Revivent-TC Ventricular Enhancement System for heart failure (HF). The hybrid procedure was performed by Prof. Petr Neuzil (interventional cardiologist) and Dr. Ivo Skalsky (cardiothoracic surgeon) on a 38-year-old female patient at the Na Holmoce Hospital in Prague, Czech Republic.   

The Less Invasive Ventricular Enhancement or the LIVE procedure, utilizing this new TransCatheter approach, is in clinical trials throughout Europe.  This case comes on the heels of other successful Revivent-TC cases performed recently in Spain, Italy, France, and Germany. 
"Before the LIVE procedure, this patient's quality of life was severely impacted by her heart failure to the point where she could no longer walk even short distances without discomfort.  The Revivent-TC system allows treatment of patients with worsening heart failure and those that are already very ill without opening the chest," said Neuzil.  

"The adoption of the Revivent-TC system allows us to treat the underlying cause of heart failure by reshaping the left ventricle to improve pumping efficiency and reduce wall stress," Skalsky added.

Recent analysis has shown that 76 percent of patients with mitral regurgitation that were treated with the Revivent technology had an added benefit of improvement in mitral valve functionality.  

BioVentrix has reported an average reduction of 31 percent in Left Ventricular volume and a 14 percent improvement ejection fraction (EF) at one-year post-op follow-up. The data continues to show the same volume reduction and ejection fraction increase with this hybrid approach as was demonstrated with the previous surgical technique.

Placement of the Revivent-TC System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a closed-chest, TransCatheter approach. The anchors are then pulled toward one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion.

For more information:

Related Content

Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Overlay Init